The proliferation markers Ki-67/MIB-1, phosphohistone H3, and survivin may contribute in the identification of aggressive ovarian carcinomas

International Journal of Clinical and Experimental Pathology

Volumn 4, Issue 5, 2011, Pages 444-453

  Aune, Guro ^a   Stunes, Astrid K ^a   Tingulstad, Solveig ^b   Salvesen, Øyvind ^a   Syversen, Unni ^a,c   Torp, Sverre H ^b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b Children's and Women's Health ^*  (Norway)

^c TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Diagnosis; Ki 67 MIB 1; Ovarian carcinoma; Ovary; PHH3; Proliferation; Survival; Survivin

Indexed keywords

BIRC5 PROTEIN, HUMAN; CYSTEINE PROTEINASE INHIBITOR; HISTONE; INHIBITOR OF APOPTOSIS PROTEIN; KI 67 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CARCINOMA; CELL PROLIFERATION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MITOSIS INDEX; OVARY TUMOR; PATHOLOGY; PHOSPHORYLATION; PREDICTIVE VALUE; PROGNOSIS;

ADULT; AGED; CARCINOMA; CELL PROLIFERATION; CYSTEINE PROTEINASE INHIBITORS; FEMALE; HISTONES; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITOR OF APOPTOSIS PROTEINS; KI-67 ANTIGEN; MIDDLE AGED; MITOTIC INDEX; NEOPLASM INVASIVENESS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PHOSPHORYLATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 80055042842     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Tavassoli FA and Devilee P: Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Edited by Kleihues P, Sobin LH. Lyon, International Agency for Research on Cancer, 2003
2. Colombo N, Van Gorp T, Parma G, Amant F, Gatta G, Sessa C and Vergote I. Ovarian cancer. Crit Rev Oncol Hematol 2006; 60: 159-179.
3. Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F and Capocaccia R. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer 2009; 45: 931-991.
4. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
5. Armstrong DK and Brady MF. Intraperitoneal therapy for ovarian cancer: a treatment ready for prime time. J Clin Oncol 2006; 24: 4531-4533.
6. Clark TG, Stewart ME, Altman DG, Gabra H and Smyth JF. A prognostic model for ovarian cancer. Br J Cancer 2001; 85: 944-952.
7. Garzetti GG, Ciavattini A, Goteri G, De Nictolis M, Stramazzotti D, Lucarini G and Biagini G. Ki67 antigen immunostaining (MIB 1 monoclonal antibody) in serous ovarian tumors: index of proliferative activity with prognostic significance. Gynecol Oncol 1995; 56: 169-174.
8. Sengupta PS, McGown AT, Bajaj V, Blackhall F, Swindell R, Bromley M, Shanks JH, Ward T, Buckley CH, Reynolds K, Slade RJ and Jayson GC. p53 and related proteins in epithelial ovarian cancer. Eur J Cancer 2000; 36: 2317-2328.
9. Cannistra SA. Cancer of the ovary. N Engl J Med 2004; 351: 2519-2529.
10. Linden MD, Torres FX, Kubus J and Zarbo RJ. Clinical application of morphologic and immunocytochemical assessments of cell proliferation. Am J Clin Pathol 1992; 97: S4-13.
11. Cattoretti G, Becker MH, Key G, Duchrow M, Schluter C, Galle J and Gerdes J. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalinfixed paraffin sections. J Pathol 1992; 168: 357-363.
12. Pollack A, DeSilvio M, Khor LY, Li R, Al-Saleem TI, Hammond ME, Venkatesan V, Lawton CA, Roach M, 3rd, Shipley WU, Hanks GE and Sandler HM. Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02. J Clin Oncol 2004; 22: 2133-2140.
13. Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell'Orto P, Maiorano E, MacGrogan G, Braye SG, Ohlschlegel C, Neven P, Orosz Z, Olszewski WP, Knox F, Thurlimann B, Price KN, Castiglione-Gertsch M, Gelber RD, Gusterson BA and Goldhirsch A. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 2008; 26: 5569-5575.
14. Margulis V, Lotan Y, Karakiewicz PI, Fradet Y, Ashfaq R, Capitanio U, Montorsi F, Bastian PJ, Nielsen ME, Muller SC, Rigaud J, Heukamp LC, Netto G, Lerner SP, Sagalowsky AI and Shariat SF. Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. J Natl Cancer Inst 2009; 101: 114-119.
15. Petrowsky H, Sturm I, Graubitz O, Kooby DA, Staib-Sebler E, Gog C, Kohne CH, Hillebrand T, Daniel PT, Fong Y and Lorenz M. Relevance of Ki-67 antigen expression and K-ras mutation in colorectal liver metastases. Eur J Surg Oncol 2001; 27: 80-87.
16. Kritpracha K, Hanprasertpong J, Chandeying V, Dechsukhum C and Geater A. Survival analysis in advanced epithelial ovarian carcinoma in relation to proliferative index of MIB-1 immunostaining. J Obstet Gynaecol Res 2005; 31: 268-276.
17. Mishra SK and Crasta JA. An immunohistochemical comparison of P53 and Bcl-2 as apoptotic and MIB1 as proliferative markers in lowgrade and high-grade ovarian serous carcinomas. Int J Gynecol Cancer 2010; 20: 537-541.
18. Ribalta T, McCutcheon IE, Aldape KD, Bruner JM and Fuller GN. The mitosis-specific antibody anti-phosphohistone-H3 (PHH3) facilitates rapid reliable grading of meningiomas according to WHO 2000 criteria. Am J Surg Pathol 2004; 28: 1532-1536.
19. Skaland I, Janssen EA, Gudlaugsson E, Klos J, Kjellevold KH, Soiland H and Baak JP. Phosphohistone H3 expression has much stronger prognostic value than classical prognosticators in invasive lymph node-negative breast cancer patients less than 55 years of age. Mod Pathol 2007; 20: 1307-1315.
20. Fukushima S, Terasaki M, Sakata K, Miyagi N, Kato S, Sugita Y and Shigemori M. Sensitivity and usefulness of anti-phosphohistone-H3 antibody immunostaining for counting mitotic figures in meningioma cases. Brain Tumor Pathol 2009; 26: 51-57.
21. Tapia C, Kutzner H, Mentzel T, Savic S, Baumhoer D and Glatz K. Two mitosis-specific antibodies, MPM-2 and phospho-histone H3 (Ser28), allow rapid and precise determination of mitotic activity. Am J Surg Pathol 2006; 30: 83-89.
22. Takahashi H, Murai Y, Tsuneyama K, Nomoto K, Okada E, Fujita H and Takano Y. Overexpression of phosphorylated histone H3 is an indicator of poor prognosis in gastric adenocarcinoma patients. Appl Immunohistochem Mol Morphol 2006; 14: 296-302.
23. Scott IS, Heath TM, Morris LS, Rushbrook SM, Bird K, Vowler SL, Arends MJ and Coleman N. A novel immunohistochemical method for estimating cell cycle phase distribution in ovarian serous neoplasms: implications for the histopathological assessment of paraffin-embedded specimens. Br J Cancer 2004; 90: 1583-1590.
24. Chen YJ, Chen CM, Twu NF, Yen MS, Lai CR, Wu HH, Wang PH and Yuan CC. Overexpression of Aurora B is associated with poor prognosis in epithelial ovarian cancer patients. Virchows Arch 2009; 455: 431-440.
25. Ferrandina G, Legge F, Martinelli E, Ranelletti FO, Zannoni GF, Lauriola L, Gessi M, Gallotta V and Scambia G. Survivin expression in ovarian cancer and its correlation with clinicopathological, surgical and apoptosis-related parameters. Br J Cancer 2005; 92: 271-277.
26. Sui L, Dong Y, Ohno M, Watanabe Y, Sugimoto K and Tokuda M. Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors. Int J Oncol 2002; 21: 315-320.
27. No JH, Jeon YT, Kim YB and Song YS. Quantitative detection of serum survivin and its relationship with prognostic factors in ovarian cancer. Gynecol Obstet Invest 2011; 71: 136-140.
28. Takai N, Miyazaki T, Nishida M, Nasu K and Miyakawa I. Expression of survivin is associated with malignant potential in epithelial ovarian carcinoma. Int J Mol Med 2002; 10: 211-216.
29. Qian X, Xi X and Li L. Nuclear survivin is associated with malignant potential in epithelial ovarian carcinoma. Appl Immunohistochem Mol Morphol 2011; 19: 126-132.
30. Benedet JL, Bender H, Jones H, 3rd, Ngan HY and Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 2000; 70: 209-262.
31. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
32. Huettner PC, Weinberg DS and Lage JM. Assessment of proliferative activity in ovarian neoplasms by flow and static cytometry. Correlation with prognostic features. Am J Pathol 1992; 141: 699-706.
33. Wong WS and Tattersall MH. Immunohistochemical determination of tumour growth fraction in human ovarian carcinoma. Br J Obstet Gynaecol 1989; 96: 720-724.
34. Isola J, Kallioniemi OP, Korte JM, Wahlstrom T, Aine R, Helle M and Helin H. Steroid receptors and Ki-67 reactivity in ovarian cancer and in normal ovary: correlation with DNA flow cytometry, biochemical receptor assay, and patient survival. J Pathol 1990; 162: 295-301.
35. Abry E, Thomassen IO, Salvesen OO and Torp SH. The significance of Ki-67/MIB-1 labeling index in human meningiomas: a literature study. Pathol Res Pract 2010; 206: 810-815.
36. Sui L, Dong YY, Ohno M, Watanabe Y, Sugimoto K and Tokuda M. Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors. International Journal of Oncology 2002; 21: 315-320.
37. Zaffaroni N, Pennati M, Colella G, Perego P, Supino R, Gatti L, Pilotti S, Zunino F and Daidone MG. Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cellular and Molecular Life Sciences 2002; 59: 1406-1412.
38. Li F. Role of survivin and its splice variants in tumorigenesis. Br J Cancer 2005; 92: 212-216.
39. Li F, Yang J, Ramnath N, Javle MM and Tan D. Nuclear or cytoplasmic expression of survivin: what is the significance? Int J Cancer 2005; 114: 509-512.
40. Layfield LJ, Saria EA, Berchuck A, Dodge RK, Thompson JK, Conlon DH and Kerns BJ. Prognostic value of MIB-1 in advanced ovarian carcinoma as determined using automated immunohistochemistry and quantitative image analysis. J Surg Oncol 1997; 66: 230-236; discussion 236-237.
41. Mita S, Nakai A, Maeda S and Takeshita T. Prognostic significance of Ki-67 antigen immunostaining (MIB-1 monoclonal antibody) in ovarian cancer. J Nippon Med Sch 2004; 71: 384-391.
42. Kommoss S, du Bois A, Schmidt D, Parwaresch R, Pfisterer J and Kommoss F. Chemotherapy may be more effective in highly proliferative ovarian carcinomas--a translational research subprotocol of a prospective randomized phase III study (AGO-OVAR 3 protocol). Gynecol Oncol 2006; 103: 67-71.